logo-loader
viewCheck Cap Ltd.

Check Cap soars on positive clinical results for its patient-friendly C-Scan screening test

The Israel-based company is developing the first capsule-based system for colorectal cancer screening

Check-Cap's preparation-free, non-invasive, high-resolution colon imaging system
Shares moved sharply on news of the less invasive

Shares of Check Cap Ltd. (NASDAQ:CHEK) soared on Tuesday in response to positive clinical study results for its patient-friendly C-Scan, which is the first capsule-based system for colorectal cancer screening.   

Check Cap popped nearly 8% to US$5 in morning trade.

The Isfiya, Israeli, clinical-stage medical-diagnostics company, is focused on the development of a capsule-based system that utilizes low-dose X-rays for colon screening to detect structural abnormalities that may be precancerous or cancerous polyps and colorectal cancers.

Unlike existing tests, C-Scan combines X-ray and location info to create a 3D map of the contours on the inside of the colon for physician review.

A study published in the British journal Gut highlighted the value proposition of C-Scan compared to a traditional screening test called fecal immunochemical test (FIT).

In 45 patients, the sensitivity of C-Scan was 44% compared to 37% for FIT. C-Scan's sensitivity increased to 78% when more than 50% of the colon surface area was imaged through colonoscopy.

In a retrospective analysis using an updated scanning algorithm, the sensitivity of C-Scan rose to 91% in cases were more than half of the colon was imaged.

Designed to be patient-friendly, C-Scan is hoping to increase people’s willingness to go through recommended annual colorectal cancer screening. The Israeli firm’s preparation-free screening gets rid of frequently-cited barriers linked to more invasive screening methods requiring sedatives.

Quick facts: Check Cap Ltd.

Price: 1.42 USD

NASDAQ:CHEK
Market: NASDAQ
Market Cap: $11.74 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks lift; Canopy Growth names Constellation Brands...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, lifted 1.7% higher at 111.3 points. Elsewhere, the Horizons Marijuana Life Sciences Index ETF grew 1.8% to C$9.13, while the OTCQX Cannabis index rose 1.3% to 432.3 points. Buds today are Canopy...

5 hours, 43 minutes ago

2 min read